Overall Status

Completed (23)

Terminated (2)

Active, not recruiting (1)

Recruiting (1)

Unknown status (1)

Withdrawn (1)

Phase

phase 2 (12)

phase 1 (11)

phase 3 (3)

phase 1/phase 2 (2)

Sponsor

Amgen (18)

National Cancer Institute (NCI) (4)

Austin Health (1)

Dana-Farber Cancer Institute (1)

OmicsWay Corp. (1)

QuantumLeap Healthcare Collaborative (1)

Roswell Park Cancer Institute (1)

Takeda (1)

University of Colorado, Denver (1)

Collaborator

Amgen (3)

Kaluga Regional Clinical Oncology Center (1)

Multidisciplinary medical holding SM-Clinic (1)

N.N. Blokhin National Medical Research Center of Oncology (1)

Oncobox Ltd (1)

Oncological Clinical Dispensary No. 1 of the Moscow City Health Department (1)

Vitamed LLC (1)

Study Documents

Intervention Type

drug (27)

other (5)

biological (4)

procedure (1)

Funder Type

Industry (20)

Other (5)

NIH (4)

Study Type

Interventional (28)

Observational (1)

Trebananib

Showing 26 - 29 of 29

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Advanced Solid Tumors Trial in Aurora, Salt Lake City (AMG 386, Paclitaxel)

Completed

Advanced Solid Tumors

AMG 386
Paclitaxel

Aurora, Colorado
+1 more

Sep 19, 2014

Gastrointestinal Cancer Trial (AMG 386 , AMG 386 10mg/kg, AMG 386 3mg/kg)

Completed

Gastrointestinal Cancer

AMG 386 placebo
+4 more

(no location specified)

Apr 21, 2014

Metastatic Colorectal Cancer Trial in Melbourne (AMG386 and bevacizumab)

Unknown status

Metastatic Colorectal Cancer

AMG386 and bevacizumab

Melbourne, Victoria, Australia

Austin Health

Nov 29, 2010

Tumors Trial (AMG 386)

Completed

Tumors

AMG 386

(no location specified)

Aug 19, 2010